secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2022-12-05T23:59:59+00:00
Accession:  0001193125-22-298474
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara Inc. announces expiration of HSR Act waiting period for merger with Enliven Therapeutics
--------------------------------------------------------------------------------

- HSR Act waiting period for merger with Enliven Therapeutics expired on Nov 28, 2022, without extension or request for additional information.
- This expiration satisfies one of the conditions to closing the merger previously announced on Oct 13, 2022.
- Upon closing, Merger Sub will merge with Enliven, making Enliven a wholly-owned subsidiary of Imara.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312522298474/0001193125-22-298474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312522298474/d415058d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-298474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer